Details for Patent: 8,207,297
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,207,297 protect, and when does it expire?
Patent 8,207,297 protects KYPROLIS and is included in one NDA.
This patent has ninety patent family members in twenty-six countries.
Summary for Patent: 8,207,297
Title: | Compounds for enzyme inhibition |
Abstract: | Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. |
Inventor(s): | Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA) |
Assignee: | Onyx Therapeutics, Inc. (South San Francisco, CA) |
Application Number: | 13/334,469 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,207,297 |
Patent Claim Types: see list of patent claims | Use; Process; Composition; Formulation; Dosage form; Compound; |
Drugs Protected by US Patent 8,207,297
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,207,297
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 494298 | See Plans and Pricing | |||
Austria | 496062 | See Plans and Pricing | |||
Australia | 2005238445 | See Plans and Pricing | |||
Australia | 2005271232 | See Plans and Pricing | |||
Australia | 2005295183 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |